Zura Bio Ltd
No enriched coverage for $ZURA in the last 7 days.
No SEC Form 4 filings for $ZURA in the last 30 days.
The article highlights 10 growth stocks with increased insider ownership, using a Finviz screen and criteria including at least 20% compounded earnings growth over three years. It cites analyst actions and company updates for Sonida Senior Living (SNDA) and Zura Bio (ZURA), including SNDA price target raises to $48 and ZURA Phase 2 enrollment and $225.6M cash.
Zura Bio (NASDAQ:ZURA) is advancing tibulizumab. According to analyst Matt Phipps, the drug’s dual inhibition of T- and B-cell inflammatory pathways could improve outcomes in autoimmune diseases. Zura completed Phase 2 enrollment in TibuSHIELD for hidradenitis suppurativa, with topline data expected in Q4 2026; TibuSURE in 1H 2027. Phipps projects $2.3B peak HS sales (NPV $8.04/share) and William Blair projects $1.6B peak SSc sales (NPV $4.51/share). Zura reported $225.6M cash as of Mar 31, 2026
Clear Street names five biotech stocks for 2H 2026 catalysts: MoonLake (MLTX) Buy, $70 target; Cullinan (CGEM) Buy, $46; Zura Bio (ZURA) Buy, $18; Arrivent (AVBP) Buy, $47; Protagonist (PTGX) Buy, $116. It cites planned clinical readouts and regulatory milestones, plus MLTX’s ~$200M offering and AVBP’s up to $250M ATM filing.
Recent ZURA coverage spans financial news, technology and sector analysis.
Clinical-trial enrollment completion and updated readouts can re-rate probability-weighted outcomes for tibulizumab programs.
Trial-enrollment progress and forward timelines support a bullish catalyst path, but the article provides no new clinical efficacy datapoint yet.
Enrollment completion plus a defined 4Q26 data trigger creates a clear near-to-mid-term catalyst calendar for ZURA.
Board/officer changes and updated compensatory arrangements can affect near-term governance and incentive-driven behavior, but the excerpt provides no specific new personnel terms.
The amended passive investment disclosure reveals that institutional investors collectively hold 9.9% of Zura Bio Ltd, with detailed voting and ownership rights. This may signal increased institutional interest, potentially affecting stock stability and liquidity.
alphai scores every news story that mentions ZURA with an AI model for sentiment and relevance, and aggregates insider trades from Zura Bio Ltd's SEC EDGAR Form 4 filings. Figures refresh continuously.
The article highlights 10 growth stocks with increased insider ownership, using a Finviz screen and criteria including at least 20% compounded earnings growth over three years. It cites analyst actions and company updates for Sonida Senior Living (SNDA) and Zura Bio (ZURA), including SNDA price target raises to $48 and ZURA Phase 2 enrollment and $225.6M cash.
7 min readZura Bio (NASDAQ:ZURA) is advancing tibulizumab. According to analyst Matt Phipps, the drug’s dual inhibition of T- and B-cell inflammatory pathways could improve outcomes in autoimmune diseases. Zura completed Phase 2 enrollment in TibuSHIELD for hidradenitis suppurativa, with topline data expected in Q4 2026; TibuSURE in 1H 2027. Phipps projects $2.3B peak HS sales (NPV $8.04/share) and William Blair projects $1.6B peak SSc sales (NPV $4.51/share). Zura reported $225.6M cash as of Mar 31, 2026
4 min readClear Street names five biotech stocks for 2H 2026 catalysts: MoonLake (MLTX) Buy, $70 target; Cullinan (CGEM) Buy, $46; Zura Bio (ZURA) Buy, $18; Arrivent (AVBP) Buy, $47; Protagonist (PTGX) Buy, $116. It cites planned clinical readouts and regulatory milestones, plus MLTX’s ~$200M offering and AVBP’s up to $250M ATM filing.
7 min readZura Bio Ltd (ZURA) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. EX-10.1 2 tm2618327d1_ex10-1.htm EXHIBIT 10.1 Exhibit 10.1 ZURA BIO LIMITED 2023 EQUITY INCENTIVE PLAN (As Amended June 1, 2023 and June 17, 2026) 1. Purpose The purpose of this Zura Bio Limited 2023 Equity Incentive Plan (the “ Plan ”) is to promote and closely align the interes
3 min readThis SEC filing (SCHEDULE 13G/A) details an amended passive investment disclosure for Zura Bio Limited (ZURA) as of March 31, 2026. Suvretta Capital Management, LLC, Averill Master Fund, Ltd., and Aaron Cowen are identified as reporting persons, collectively holding 9.9% of Class A Ordinary Shares. The filing clarifies their beneficial ownership, voting, and dispositive powers, including details about pre-funded warrants and specific ownership percentages for each entity.
2 min read
